Evidence map›Paper›PMID 38466285›Full record

ArticleInvestigative ophthalmology & visual science2024

Isolation and Characterization of Extracellular Vesicles Through Orthogonal Approaches for the Development of Intraocular EV Therapy.

Justin Leung, Dimitrios Pollalis, Gopa K G Nair, Jeffrey K Bailey, Britney O Pennington, Amir I Khan, Kaitlin R Kelly, Ashley K Yeh, Kartik S Sundaram, Dennis O Clegg and 3 more

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Justin LeungUSC Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California, United States.
Dimitrios PollalisUSC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, California, United States.
Gopa K G NairUSC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, California, United States.
Jeffrey K BaileyCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Britney O PenningtonCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Amir I KhanCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Kaitlin R KellyCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Ashley K YehCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Kartik S SundaramCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Dennis O CleggCenter for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California, United States.
Chen-Ching PengRoski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States.
Liya XuRoski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, United States.
Sun Young LeeUSC Ginsburg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, California, United States.

Funding

Ophthalmic Therapeutics Engineering CoreP30EY029220 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mahnaz Shahidi · 2018 to 2026
$6.5M
Extracellular vesicle-based intraocular therapy combined with active targeting of ocular neovascularizationR01EY034193 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Sun Young Lee · 2024 to 2026
$1.6M
USC Roski Eye K12 Clinician-Vision Scientist Training Program (USC Roski Eye K12)K12EY028873 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HUMAYUN, MARK S · 2018 to 2023
$1.1M
Extracellular Vesicle Therapy for Diabetic RetinopathyR21EY035425 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LEE, SUN YOUNG · 2023 to 2023
$480k
Exosome based intraocular therapy combined with active targeting of ocular neovascularizationR56EY034193 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LEE, SUN YOUNG · 2022 to 2022
$417k
NEI NIH HHS K12 EY028873NEI NIH HHS P30 EY029220NEI NIH HHS R01 EY034193NEI NIH HHS R21 EY035425NEI NIH HHS R56 EY034193
6 · The paper itself

Abstract

Purpose: Isolating extracellular vesicles (EVs) with high yield, replicable purity, and characterization remains a bottleneck in the development of EV therapeutics. To address these challenges, the current study aims to establish the necessary framework for preclinical and clinical studies in the development of stem cell-derived intraocular EV therapeutics. Methods: Small EVs (sEVs) were separated from the conditioned cell culture medium (CCM) of the human embryogenic stem cell-derived fully polarized retinal pigment epithelium (hESC-RPE-sEV) by a commercially available microfluidic tangential flow filtration (TFF) device ExoDisc (ED) or differential ultracentrifugation (dUC). The scaling and concentration capabilities and purity of recovered sEVs were assessed. Size, number, and surface markers of sEVs were determined by orthogonal approaches using multiple devices. Results: ED yielded higher numbers of sEVs, ranging from three to eight times higher depending on the measurement device, compared to dUC using the same 5 mL of CCM input. Within the same setting, the purity of ED-recovered hESC-RPE-sEVs was higher than that for dUC-recovered sEVs. ED yielded a higher concentration of particles, which is strongly correlated with the input volume, up to 10 mL (r = 0.98, P = 0.016). Meanwhile, comprehensive characterization profiles of EV surface markers between ED- and dUC-recovered hESC-RPE-sEVs were compatible. Conclusions: Our study supports TFF as a valuable strategy for separating sEVs for the development of intraocular EV therapeutics. However, there is a growing need for diverse devices to optimize TFF for use in EV preparation. Using orthogonal approaches in EV characterization remains ideal for reliably characterizing heterogeneous EV.

Indexed as

Extracellular VesiclesHuman Embryonic Stem CellsCulture Media, ConditionedFiltrationHumansRetinal Pigment EpitheliumCulture Media, Conditioned

Identifiers

PMID38466285
PMCPMC10929743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.